Teva Pharmaceutical Industries Limited has grown revenue −2.1% a year over three years and −2.9% a year over five. Revenue growth, 3-year annual rate: −2.1% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: −2.9%, growth has picked up over the last three years. Years of annual history on file: 19, FY2007 to FY2025, as filed.

TEVATeva Pharmaceutical Industries Limited

Healthcare

$41.07+124% 1Y

$41.07

$18.3452 weeks$41.07

Latest close: a new 52-week highOct 9, 2026what changed →

Is it growing?

Mixed

Neither accelerating nor breaking down: operating margin widening (+7.0 points), but revenue shrinking (−15% year on year) and earnings down −475% year on year.

1 good, 2 to watch

Revenue trend−15% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −3% a year.

Earnings trend−475% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+7.0 points operating

Trailing-twelve-month operating margin, 12.6% now against 5.6% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is TEVA growing?

Teva Pharmaceutical Industries Limited has grown revenue −2.1% a year over three years and −2.9% a year over five.

−2.1%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −2.9%
Revenue growth, 5-year rate · −2.1% over three · growth has picked up over the last three years
Years of annual history on file: 19
Years of annual history on file · FY2007 to FY2025, as filed

Details›